Despite the favorable prognosis of childhood acute lymphoblastic leukemia (ALL), a substantial subset of patients relapses. As this occurs not only in the high risk but also in the standard/intermediate groups, the presently used risk stratification is suboptimal. The underlying mechanisms for treatment failure include the presence of genetic changes causing insensitivity to the therapy administered. To identify relapse-associated aberrations, we performed single-nucleotide polymorphism array analyses of 307 uniformly treated, consecutive pediatric ALL cases accrued during 1992-2011. Recurrent aberrations of 14 genes in patients who subsequently relapsed or had induction failure were detected. Of these, deletions/uniparental isodisomies of ADD3, ATP10A, EBF1, IKZF1, PAN3, RAG1, SPRED1 and TBL1XR1 were significantly more common in B-cell precursor ALL patients who relapsed compared with those remaining in complete remission. In univariate analyses, age (X10 years), white blood cell counts (4100 Â 10 9 /l), t(9;22)(q34;q11), MLL rearrangements, near-haploidy and deletions of ATP10A, IKZF1, SPRED1 and the pseudoautosomal 1 regions on Xp/Yp were significantly associated with decreased 10-year event-free survival, with IKZF1 abnormalities being an independent risk factor in multivariate analysis irrespective of the risk group. Older age and deletions of IKZF1 and SPRED1 were also associated with poor overall survival. Thus, analyses of these genes provide clinically important information.
INTRODUCTION
The cure rate for pediatric acute lymphoblastic leukemia (ALL) has improved dramatically during the past few decades, with diseasefree survival at 5 years now exceeding 80% in most current treatment protocols. 1, 2 However, the one-fifth who relapses still fares poorly, with overall survival (OS) rates of only approximately 30% despite aggressive chemotherapy and stem cell transplantation, indicating that the blasts at relapse are refractory to presently available therapeutic regimes in most instances. 1, [3] [4] [5] Hence, it is vital to identify 'relapse-prone' clones already at the time of diagnosis in order to ensure proper risk stratification and treatment decisions. Today, several clinical and genetic factors are routinely used to stratify patients into different risk groups/ treatment intensities, such as white blood cell (WBC) count, age and immunophenotypic and genetic features. 1, 2, 5, 6 However, as relapses occur not only in the high-risk group but also in the standard and intermediate groups, these factors are suboptimal.
A number of studies aiming at elucidating the underlying mechanisms for relapse has compared genetic features in paired diagnostic and relapse samples using conventional cytogenetic, 7, 8 clone-specific PCR, 9, 10 fluorescence in situ hybridization (FISH) 11, 12 and single-nucleotide polymorphism (SNP) array analyses, 4, [13] [14] [15] [16] [17] revealing that the relapsed clones can be identical to the ones seen at diagnosis, display additional changes (clonal evolution) or harbor both additional, identical as well as fewer changes (evolution from a preleukemic/ancestral clone). The two latter evolution patterns indicate outgrowth of therapy-resistant minor subclones. 4, [9] [10] [11] [12] 16, 17 In addition, high-resolution genomic profiling has identified genes, for example, CDKN2A, ETV6, IKZF1 and EBF1, that are more frequently deleted in samples from patients who subsequently relapse than in samples from those remaining in first complete remission (CR1). 4, 13, 14, 18 However, whether these deletions serve as independent prognostic markers is still unclear. 13, 14, 18, 19 In the present study, SNP array analyses were performed on diagnostic, CR1, relapse and induction failure (IF) samples from pediatric ALL patients to identify copy number aberrations and uniparental isodisomies (UPDs) associated with relapse/IF. In a next step, all identified recurrent abnormalities were screened for in diagnostic samples from patients without relapse/IF to ascertain whether they may be associated with event-free survival (EFS) and/or OS in a large patient cohort uniformly treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL protocols.
(n ¼ 138), 2000 (n ¼ 94) or 2008 (n ¼ 56) protocols. 2 The median age was 4 years, the male/female ratio 1.4 and the median WBC count 10.8 Â 10 9 /l (range 0. . Of the 307 patients, 269 (88%) had B-cell precursor (BCP) ALL, 33 (11%) T-ALL, 4 (1.3%) mature B-cell ALL and 1 (0.3%) biphenotypic leukemia. All bone marrow/peripheral blood samples were analyzed using conventional chromosome banding and targeted analyses (reverse transcriptase-PCR, FISH or Southern blot analyses). Among the BCP ALL cases, 5.6% were positive for 11q23/MLL rearrangements (251 analyzed cases), 5.2% for t(1;19)(q23;p13) (TCF3/PBX1; n ¼ 212), 2.7% for t(9;22)(q34;q11) (BCR/ABL1; n ¼ 219) and 24% for t(12;21)(p13;q22) (ETV6/ RUNX1; n ¼ 230), and 70 (26%) cases were high hyperdiploid. None of the T-ALL or mature B-cell ALL cases analyzed was positive for any of these rearrangements. The single case with biphenotypic leukemia harbored an MLL rearrangement. Basic clinical and genetic features are provided in Supplementary Table S1 .
Among the 307 patients, 60 (20%) relapsed, 44 (73%) of which were bone marrow relapses. In addition, 17 (5.5%) had IF (defined as 45% abnormal nuclei as ascertained by locus-specific FISH analyses at days 15 or 29). The median age of all the 77 patients with relapse/IF was 3.5 years (range 0-17), the male/female ratio 1.7 and the median WBC count 14.1 Â 10 9 /l (range 0.8-802). Sixty-seven (87%) of the patients had BCP ALL; the remaining 10 (13%) had T-ALL ( Table 1) .
The genetic subgroups represented among the 67 BCP ALL samples, obtained from patients with subsequent relapse/IF, comprised high hyperdiploidy (HeH, 51-67 chromosomes; 25%), t(12;21) (19%), MLL rearrangements (13%), normal karyotype (NK; 4.5%), t(9;22) (6.0% ) and near-haploidy (23-29 chromosomes; 6.0%); the remaining cases (25%) had other abnormalities or were cytogenetic failures. Among the 10 T-ALL cases, 3 had NK, 4 harbored CDKN2A deletions and 3 carried various, nonrecurrent abnormalities. The clinical and cytogenetic data of the 77 relapse/IF patients are given in Supplementary Table S2. SNP array analysis DNA was extracted, using standard methods, from bone marrow or peripheral blood cells at the time of diagnosis, CR1 and at relapse/IF. The analyses were performed using the HumanOmni1-Quid and Human1M-Duo array systems (Illumina, San Diego, CA, USA), covering 41 000 000
SNPs. The Genomestudio software 2011.1 (Illumina) was applied for analysis of copy number aberrations and UPDs; some samples were analyzed in build GRCh36.1, whereas the majority was analyzed in build GRCh37 (Supplementary Table S2 ). All recurrent aberrations detected were converted to GRCh37 coordinates (http://www.ensembl.org/Homo_sa-piens/Info/Index) to find the smallest overlap. Imbalances seen in remission samples or that overlapped with copy number polymorphisms listed in the Database of Genomic Variants (http://projects.tcag.ca/ variation/) were excluded from further analysis, and so were deletions corresponding to somatic rearrangements of the T-cell receptor and immunoglobulin loci. 16 A flowchart depicting the cases analyzed by SNP arrays is shown in Supplementary Figure S1 .
Identification of recurrent gene targets and genomic imbalances
Gene targets (in all instances, deletions) and genomic imbalances, the latter comprising partial gains and losses not involving single genes, identified in diagnostic samples from at least two patients with subsequent relapse/IF were considered recurrent. To be denoted a gene target, at least one of the samples had to display a focal deletion involving only the specified gene. All recurrent aberrations were subsequently ascertained in the entire patient cohort without relapse/IF successfully analyzed by SNP arrays (n ¼ 170).
Statistical analyses
The PASW Statistics 20 software for Windows (SPSS Inc., Chicago, IL, USA) was used for all analyses. The significance limit for two-sided P-values was set to o0.05. The frequencies of gene targets/genomic imbalances in diagnostic and relapse/IF samples were compared using the Wilcoxon signed-rank and two-tailed Fisher's exact probability tests. The 10-year (yr) probabilities of EFS (pEFS) and OS (pOS) in relation to clinical (sex, age, risk group and WBC count) and genetic features (modal chromosome number, cytogenetic subgroup and gene targets/genomic imbalances) were calculated using the Kaplan-Meier method for patients treated only according to the NOPHO ALL 1992 and 2000 protocols, as these protocols were virtually identical with regards to risk group assignment and therapy (the study cohorts are shown in Supplementary Figure S2 ). Multivariate At diagnosis, the median number of genomic imbalances per case was 7 (range 0-24), with 3 (range 0-11) duplications, 2 (range 0-12) losses (hemizygous/homozygous deletions as well as monosomies), 0 (range 0-20) whole-chromosome UPDs, 0 (range 0-2) partial UPDs (pUPDs) and 3 (range 0-20) structural changes, including pUPDs. The corresponding frequencies for the relapse/IF samples were 8 (range 0-27), 3 (range 0-11), 2 (range 0-17), 0 (range 0-20), 0 (range 0-2) and 3 (range 0-27). There were no significant differences in the total number of imbalances, duplications, whole-chromosome UPDs, pUPDs and structural changes between the paired samples, whereas losses were slightly more common at relapse/IF (P ¼ 0.048).
Genetic evolution patterns in the paired diagnostic and relapse/IF samples Seven (41%) of the 17 paired cases had identical genetic changes or harbored no genomic imbalances at diagnosis and relapse/IF. Six (35%) cases displayed additional changes at relapse/IF, indicating clonal evolution from the major diagnostic clone. An additional two (12%) cases showed clonal evolution, but in these cases the SNP array findings clearly showed that they evolved from a minor clone (subclone), and not from the major clone, as seen at diagnosis. The remaining two (12%) cases lacked some of the imbalances present at diagnosis and also exhibited novel aberrations at the time of relapse, suggesting the presence of ancestral clones from which the relapses evolved (Supplementary  Tables S3 and S4 ).
Recurrent gene targets/genomic imbalances in diagnostic samples from patients who subsequently had relapse/IF Fifty-eight diagnostic samples were informative in the SNP array analyses (Supplementary Figure S1 and Supplementary Tables S2  and S4 ). A total of 14 recurrent focal gene targets and 10 recurrent genomic imbalances were identified (Supplementary Table S5 ). Among these, the following were significantly more common in the relapse/IF group compared with the 170 successfully analyzed cases without such events: deletions/UPDs of ADD3 When focusing on only the 38 patients who relapsed, 8 target genes and 1 genomic imbalance were significantly more common than in those who did not relapse ( Table 2) .
The recurrent gene targets and genomic imbalances in cases who subsequently had relapse/IF also varied among the different BCP ALL cytogenetic subgroups (Supplementary Tables S7 and S8 ). None of the recurrent aberrations found in the HeH, near-haploid, t(9;22), der(11)(q23)/MLL and t(12;21) groups was more common in cases who subsequently relapsed. However, among the remaining BCP ALL cases, comprising those with NK, cytogenetic failure or other cytogenetic abnormalities, with relapse/IF a total of six different gene targets and two imbalances were recurrent: deletions/pUPDs of ATP10A, CDKN2A, ETV6, IKZF1, PAX5 and SPRED1 and deletion of PAR1 and del(6)(p22.2p22.2). Of these, deletions/pUPDs of ATP10A, IKZF1, SPRED1 and PAR1 Figure S3 Among the 209 BCP ALL patients, age o10 years and WBC counts o100 Â 10 9 /l were significantly associated with superior 10-yr pEFS (Figures 1a and b) , whereas only age o10 years was associated with favorable 10-yr pOS (P ¼ 0.004). Gender had no impact on pEFS or pOS (data not shown). Modal chromosome numbers showed no significant associations with pEFS or pOS, and there were no pEFS and pOS differences between the cases with (n ¼ 169) or without (n ¼ 40) known modal numbers (data not shown). Among the cytogenetic subgroups, cases with t(9;22), MLL rearrangements and near-haploidy had an inferior 10-yr pEFS compared with those with HeH, t(12;21), t(1;19), NK or other cytogenetic abnormalities (Figure 1c) . However, this did not translate into differences with regard to pOS (data not shown). Eighty-two (39%) BCP ALL cases were grouped as standard risk, 83 (40%) as intermediate risk and 44 (21%) as high risk; these groups differed significantly with regard to 10-yr pEFS (Figure 1d ) but not pOS (P ¼ 0.059).
SNP array analyses were successfully performed on 145 (69%) of the 209 BCP cases treated according to the 1992 and 2000 NOPHO protocols; there were no differences in the 10-yr pEFS (73 vs 77%, P ¼ 0.724) or the 10-yr pOS (85 vs 87%, P ¼ 0.797) between those analyzed or not. Among the gene targets/ imbalances recurrent in patients who relapsed (Table 2) , deletions of ATP10A, IKZF1, SPRED1 and PAR1 were significantly associated with decreased pEFS rates (Figure 2) . Deletions of IKZF1 and SPRED1 were also significantly associated with poor pOS (Figure 3 ).
IKZF1 deletions are an independent risk factor for decreased EFS irrespective of risk group assignment Multivariate Cox regression analyses revealed that deletions of IKZF1 were the strongest independent risk factor for inferior pEFS in BCP ALL when taken into consideration age, WBC counts, the cytogenetic subgroups NK, HeH, t(1;19), der(11)(q23)/MLL, t(12;21) and cytogenetic failures/other cytogenetic abnormalities, risk group assignment and PAR1 deletions (Table 4) . IKZF1 was still an independent risk factor when including t(9;22), near-haploidy and deletions of ATP10A and SPRED1 (significantly associated with EFS in univariate analyses; Figure 2 ).
IKZF1 deletions were more common in the high-risk group (Supplementary Table S9 ; P ¼ 0.001), but IKZF1 status was also the strongest risk factor for pEFS among the standard-and intermediate-risk groups. In contrast, the IKZF1 status was not associated with pOS; the only parameter associated with pOS in the multivariate analysis was age 410 years (data not shown).
DISCUSSION
The present large-scale SNP array analysis of a uniformly treated pediatric ALL patient cohort was undertaken for four main reasons: (i) to identify gene targets and genomic imbalances of importance for the leukemogenic process; (ii) to analyze the clonal relationship between diagnostic and relapse samples; (iii) to ascertain genetic changes that are more prevalent at diagnosis in patients with subsequent relapse/IF and hence possibly important for treatment failure; and (iv) to pinpoint genetic aberrations that confer a significant prognostic impact in unselected pediatric ALL patients. Although such issues have been addressed previously, the current study provides additional and novel data pertaining to the four above-mentioned goals. First, we investigated a population-based series, not focusing solely on high-risk ALL, 4 T-ALL, 15 specific cytogenetic subgroups in BCP ALL 16, 17 or excluding some subgroups. 13 Also, none of our patients was lost to follow-up in contrast to several previous studies, and for some of our cases the observation time was close to 20 years with a median follow-up of 10 years, whereas the maximum follow-up time has been p10 years in earlier studies, 14, 17, 18, 20, 21 (Figures 1  and 2) . Furthermore, the SNP arrays used provide higher resolution (41 M SNPs) compared with previous SNP array-based ALL studies (250 K-500 K), 4, [13] [14] [15] [16] [17] [18] making it possible to delineate imbalances in greater detail and to identify previously unknown gene targets, as exemplified below.
Among the recurrent gene targets (Table 2) , focal deletions of SPRED1 have never been reported before. The reason for this may partly be due to the smaller number of samples analyzed in most of the previous studies, because when reviewing the Supplementary Data from published SNP array analyses of ALL, 4,13,14,16 we identified only one relapse sample, reported by Mullighan et al., 4 with a deletion including SPRED1 among other genes; this is the only previous study comprising a similar number of patients as our study. Furthermore, it is possible that the higher resolution of our SNP arrays could be an additional reason, as two of our SPRED1 deletions were small focal deletions that could have escaped detection in previous studies. SPRED1 is highly expressed in hematopoietic cells and acts as a negative regulator of RAS/ RAF/MAPK (mitogen-activated protein kinase). Germline loss-offunction mutations of the SPRED1 result in increased RAS-MAPK signal transduction and cause Legius syndrome, a disorder that displays a 'mild' neurofibromatosis type 1 phenotype and that may be associated with acute myeloid leukemia. 22 ,23 SPRED1 has previously not been implicated in ALL but mutations of other RTK-RAS genes, such as FLT3, KRAS, NRAS and PTPN11, have been reported to be enriched at ALL relapses. 16, 24 The only genomic imbalance significantly associated with relapse (Table 2 ) was del(6)(p22.2p22.2), involving the histone Relapsed pediatric ALL L Olsson et al genes HIST1H2BD and HIST1H1E in the smallest overlapping region. HIST1H2BD and HIST1H1E are part of the nucleosome structure of the chromosomal fiber and essential for cytokinesis. 25 Although these genes have not been reported to be deleted in ALL or otherwise associated with this disease, the observed 6p imbalances overlap to some extent with 6p deletions reported in Down syndrome-associated ALL and other histone clusters on 6p have been shown be deleted in pediatric ALL, with methylation arrays suggesting that histone deletions are associated with methylation alterations. 26, 27 Thus, HIST1H2BD and HIST1H1E may be added to the growing list of acute leukemia-associated genes, for example DNMT3, EZH2, HOX family and MLL, that contribute to the leukemogenic process through deregulated CpG methylation or histone modification. [28] [29] [30] [31] Among the other recurrent gene targets, most-CDKN2A, EBF1, ETV6, IKZF1, PAX5, RAG1 and TBL1XR1-have been thoroughly discussed previously. 17, 19, 27, 32, 33 However, three of the presently identified gene targets, ADD3, ATP10A and PAN3, have been less emphasized in previous studies. ADD3 has an important role in the skeletal organization of the cell membrane in erythrocytes, 34 ATP10A is an aminophospholipid translocase responsible for transporting amphipathic molecules, 35 and PAN3 is involved in degradation of poly(A) tails in cytoplasmic mRNA. 36 Both ADD3
and PAN3 have been reported to have a role in ALL-ADD3 is a NUP98 partner in T-ALL 37 and significantly associated with a gene expression cluster group with poor outcome in high-risk BCP ALL, 38 and PAN3 is recurrently deleted in HeH ALL. 39 Previous to this report, deletions of ATP10A have not been clearly associated with ALL. However, when reviewing Supplementary Data published by Mullighan et al., 4 we identified two high-risk ALL cases with deletion of this gene.
It is worthy of note that PAN3 was the only gene target specifically associated with a particular cytogenetic subgroup-all PAN3 deletions were identified in the HeH subgroup. The other gene targets were either involved in at least two cytogenetic subgroup, such as ADD3, SPRED1 and RAG1 in HeH-and t(12;21)-positive BCP ALLs, or, as CDKN2A and PAX5, in all BCP ALL subtypes, strongly suggesting that different cytogenetic subgroups evolve through similar co-operative submicroscopic changes.
The analyses of the paired samples revealed that the relapse/IF clones, in relation to those present at diagnosis, were identical, displayed clonal evolution or reflected evolution from an ancestral clone, that is, a preleukemic clone from which both the diagnostic and the relapse clones evolve; the latter clones may hence harbor both additional and identical, as well as fewer, changes when Table S3) . 4 This agrees well with previous immunogenotypic, FISH and cytogenetic studies of ALL. [7] [8] [9] [10] [11] [12] However, in contrast to previous SNP array-based analyses, 4,13,14 we identified fewer clones arising from ancestral clones and more identical clones at the time of the event. This may partly be due to the fact that we also analyzed IF samples, of which 3 of the 4 showed identical clones, indicating that the time to this event is too short for evolution to occur. In fact, when considering only the cases with relapse, 4 of the 13 showed identical clones at diagnosis and relapse, well in agreement with Kawamata et al.
compared (Supplementary
14 who reported identical clones in 4 of the 14 cases. Furthermore, the higher frequencies of evolution from ancestral clones reported by Mullighan et al. 4 and Yang et al.
13
may partly be due to the fact that they either only studied highrisk cases or included a larger number of such cases, as both highrisk cases analyzed in our diagnosis/relapse cohort displayed clonal evolution from ancestral clones. Nor did we observe any significant frequency differences with regard to genomic imbalances/UPDs between diagnostic and relapse/IF samples, as previously reported, 4, 13, 16 apart from a slightly increased frequency of deletions at relapse. This may be due to the fact that we investigated a consecutive series of patients as similar findings were also reported in a previous population-based study. 18 It should be stressed, however, that the present results do not refute that specific subgroups, such as HeH and t(12;21), may harbor more changes at relapse. 16, 17 Gene targets overrepresented in, or even unique for, relapse samples are most likely associated with treatment resistance and hence important to identify already at the time of diagnosisperhaps being present only in a minor diagnostic subclone 40 -in order to adjust treatment accordingly. We identified deletions of MSH6, BTG1 and NR3C1 to be enriched at relapse. MSH6 is a critical component of the DNA mismatch repair system, and it has been shown that decreased MSH6 expression is associated with relapse and drug insensitivity in childhood BCP ALL. 13 BTG1 is antiproliferative and acts as a cofactor involved in transcriptional regulation, mRNA turnover, and histone modification.
41 BTG1 deletions have retrospectively been found in subclones present at diagnosis that subsequently became the major clones at relapse, 42 and loss of BTG1 expression causes glucocorticoid resistance in ALL cell lines. 43 Although requirements of glucocorticoid receptors for glucocorticoid-induced response is well known, acquired aberrations of the glucocorticoid receptor-encoding gene NR3C1 have previously been considered a rare contributor to ALL relapse. 44 However, our findings add to a previous study showing NR3C1 deletions to be enriched in relapse samples from BCP ALL patients. 4 Furthermore, NR3C1 abnormalities initially observed at relapse have retrospectively been detected in subclones at diagnosis, something that most likely contributes to the glucocorticoid resistance in such cases. 40 Thus, taken together, aberrations of MSH6, BTG1 and NR3C1 may influence treatment response.
In recent years, a few genetic changes in T-ALL have been shown to correlate with outcome, such as aberrant expression of TAL1, LYL1 and TLX3. 45 However, for the majority of aberrations identified in T-ALL, either no such impact is seen or remains to be elucidated. In fact, to the best of our knowledge, no T-ALLassociated genetic changes are at present used in clinical routine to stratify patients into different risk groups. So, perhaps not surprisingly, we were unable to pinpoint any gene targets or genomic imbalances that could be used for prognostication and thus treatment stratification of T-ALL in general. In contrast to T-ALL, several clinical and genetic features were associated with outcome of BCP ALL, with the following significantly associated with a poor 10-yr EFS in univariate analyses: age X10 years, WBC counts X100 Â 10 9 /l and the presence of BCR/ABL1, MLL rearrangement and near-haploidy (Figure 1) . Furthermore, three gene targets and one genomic imbalance were also significantly associated with a poor 10-yr EFS, namely ATP10A, IKZF1, SPRED1 and PAR1 deletions (Figure 2) . Deletions of EBF1 showed a trend towards conferring decreased 10-yr EFS (P ¼ 0.055). EBF1 is a transcription factor that has a central role in the development of normal B-cells, and aberrations of this gene are clearly involved in the leukemogenic process. 13, 27, 46 High age and deletions of IKZF1 and SPRED1 were also significantly associated with a poor 10-yr OS (Figure 3 ). The present finding that deletions of SPRED1 are recurrent and that they provide a negative prognostic impact in BCP ALL is clinically important, not least considering that SPRED1 is part of MAPK signaling and that inhibitors of this pathway currently are undergoing clinical trials and hence may be novel therapeutic options. 24 The multivariate analyses strongly indicated that IKZF1 deletions were the strongest independent risk factor for poor outcome ( Table 4 ). The transcription factor IKZF1 is essential for B-cell development, with loss of IKZF1 leading to arrest of lymphoid differentiation. 46 ,47 IKZF1 abnormalities were initially associated with an inferior outcome of high-risk BCP ALL only, 21, 48 but the present data and two previous studies 18, 20 clearly show that IKZF1 aberrations also predict poor outcome in the standardand intermediate-risk groups. In our series, deletions/pUPDs of IKZF1 were the only genetic change significantly associated with relapse in cases without any known risk-stratifying aberrations (Table 3) , as also reported in a previous study. 21 Furthermore, we and others 13, 18 show that all IKZF1 lesions at diagnosis are preserved at relapse, again supporting the poor prognostic impact of IKZF1 aberrations.
Deletions involving the PAR1 region, associated with deregulation of CRLF2, 49, 50 were also a significant independent risk factor (Table 4) . However, all samples with PAR1 deletions from patients with subsequent relapse/IF also harbored IKZF1 deletions, whereas Table S10 ) and the number of cases is small, it does not negate an important prognostic impact of SPRED1 in BCP ALL, not least as all cases with SPRED1 deletions relapsed or had IF. Thus, we suggest that analyses of IKZF1 and SPRED1 at diagnosis provide clinically important information and that the IKZF1 status should be risk stratifying in future study protocols, in agreement with a recent study, 51 whereas further investigations of SPRED1 aberrations are needed to elucidate their independent prognostic impact.
